Cargando…
Integrative Analysis Revealed LINC00847 as a Potential Target of Tumor Immunotherapy
Lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer-related death. Lung adenocarcinoma (LUAD) is the most common form of lung cancer and has a low 5-year survival rate. Therefore, much more research is needed to identify cancer biomarkers, promote biomarker-drive...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511587/ https://www.ncbi.nlm.nih.gov/pubmed/36864364 http://dx.doi.org/10.1007/s12010-023-04387-z |
_version_ | 1785108175449489408 |
---|---|
author | Chen, Xiujuan Zhang, Le |
author_facet | Chen, Xiujuan Zhang, Le |
author_sort | Chen, Xiujuan |
collection | PubMed |
description | Lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer-related death. Lung adenocarcinoma (LUAD) is the most common form of lung cancer and has a low 5-year survival rate. Therefore, much more research is needed to identify cancer biomarkers, promote biomarker-driven therapy and improve treatment outcomes. LncRNAs have been reported to participate in various physiological and pathological processes, especially in cancer, and thus have attracted much attention. In this study, lncRNAs were screened from the single-cell RNA-seq dataset CancerSEA. Among them, four lncRNAs (HCG18, NNT-AS1 and LINC00847 and CYTOR) were closely associated with the prognosis of LUAD patients according to Kaplan–Meier analysis. Further study explored the correlations between these four lncRNAs and immune cell infiltration in cancer. In LUAD, LINC00847 was positively correlated with the immune infiltration of B cells, CD8 T cells, and dendritic cells. LINC00847 decreased the expression of PD-L1, immune checkpoint blockade (ICB) immunotherapy-related gene, which suggests that LINC00847 is a potential new target for tumor immunotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12010-023-04387-z. |
format | Online Article Text |
id | pubmed-10511587 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-105115872023-09-22 Integrative Analysis Revealed LINC00847 as a Potential Target of Tumor Immunotherapy Chen, Xiujuan Zhang, Le Appl Biochem Biotechnol Original Article Lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer-related death. Lung adenocarcinoma (LUAD) is the most common form of lung cancer and has a low 5-year survival rate. Therefore, much more research is needed to identify cancer biomarkers, promote biomarker-driven therapy and improve treatment outcomes. LncRNAs have been reported to participate in various physiological and pathological processes, especially in cancer, and thus have attracted much attention. In this study, lncRNAs were screened from the single-cell RNA-seq dataset CancerSEA. Among them, four lncRNAs (HCG18, NNT-AS1 and LINC00847 and CYTOR) were closely associated with the prognosis of LUAD patients according to Kaplan–Meier analysis. Further study explored the correlations between these four lncRNAs and immune cell infiltration in cancer. In LUAD, LINC00847 was positively correlated with the immune infiltration of B cells, CD8 T cells, and dendritic cells. LINC00847 decreased the expression of PD-L1, immune checkpoint blockade (ICB) immunotherapy-related gene, which suggests that LINC00847 is a potential new target for tumor immunotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12010-023-04387-z. Springer US 2023-03-03 2023 /pmc/articles/PMC10511587/ /pubmed/36864364 http://dx.doi.org/10.1007/s12010-023-04387-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Chen, Xiujuan Zhang, Le Integrative Analysis Revealed LINC00847 as a Potential Target of Tumor Immunotherapy |
title | Integrative Analysis Revealed LINC00847 as a Potential Target of Tumor Immunotherapy |
title_full | Integrative Analysis Revealed LINC00847 as a Potential Target of Tumor Immunotherapy |
title_fullStr | Integrative Analysis Revealed LINC00847 as a Potential Target of Tumor Immunotherapy |
title_full_unstemmed | Integrative Analysis Revealed LINC00847 as a Potential Target of Tumor Immunotherapy |
title_short | Integrative Analysis Revealed LINC00847 as a Potential Target of Tumor Immunotherapy |
title_sort | integrative analysis revealed linc00847 as a potential target of tumor immunotherapy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511587/ https://www.ncbi.nlm.nih.gov/pubmed/36864364 http://dx.doi.org/10.1007/s12010-023-04387-z |
work_keys_str_mv | AT chenxiujuan integrativeanalysisrevealedlinc00847asapotentialtargetoftumorimmunotherapy AT zhangle integrativeanalysisrevealedlinc00847asapotentialtargetoftumorimmunotherapy |